Rounds with the Investigators 2012 | Breast Cancer
DR NEIL LOVE: We got a couple of cases from an oncologist in a small town in Illinois, and both of the patients have — I’m not going to identify the insurance company, but apparently not very good insurance that this doc takes and nobody else does. But both patients, the lack of coverage actually affected the management. And they’re both young women that this physician is asking about, Sara. The first one’s 38. Again, difficult time, wasn’t able to get worked up because of the lack of insurance coverage.
Rounds with the Investigators 2012 | Breast Cancer
QUESTION: What do you do with a woman in her late eighties or nineties, very vigorous, with a HER2-positive tumor? This is coming up fairly frequently.
DR HAROLD BURSTEIN: With regard to the 90-year-old, I would treat her very gently, and maybe a little touch of paclitaxel/trastuzumab, as we’ve talked about for some of our other low-risk patients, and see how she does.
DR SARA HURVITZ: Would you use vinorelbine?
DR BURSTEIN: I could. Sure.
DR LOVE: Is there an age limit to your T-DM1 adjuvant trial coming up?
These audio proceedings from an Independent Satellite Symposium held at the 2012 ASCO Annual meeting offer the perspectives of 5 renowned international clinical investigators on a number of controversial management and research issues.
This content is available in a number of formats for listening on the go with a mobile device or at home on a computer.
In these audio proceedings from a symposium held in conjunction with the Oncology Nursing Society's 2012 Annual Congress, the invited oncology nursing professionals participating as part of our faculty panel present actual patient cases from their practices, setting the stage for faculty discussion of optimal therapeutic and supportive care strategies in multiple myeloma.
This content is available in a number of formats for listening on the go with a mobile device or in the office or at home on a computer.
Attal M et al. Maintenance treatment with lenalidomide after transplantation for myeloma: Analysis of secondary malignancies within the IFM 2005-02 trial. Proc International Myeloma Workshop 2011. Abstract
Davies FE et al. Are there benefits to long-term bisphosphonate treatment in multiple myeloma (MM)? Insights from temporal analyses of zoledronic acid (ZOL) versus clodronate (CLO) in the MRC Myeloma IX trial. Proc ASCO 2011;Abstract 8011.
Using a fast-moving and conversational approach devoid of didactic presentations, this webcast series was designed to profile the people, papers and concepts that are shaping current clinical decision-making in a number of important cancer types. Each archived episode features 2 expert faculty members reviewing recent data, discussing challenging cases and responding to audience questions.
Click below to view any of the recorded video proceedings from the RTP TV webcast series. These CME activities feature video, PowerPoint and related web links.
National Patterns of Care Study of Clinical Investigators and Practicing Oncologists
Practice Patterns Among Webcast Viewers